Programme

7:45 – 8:30am

Registration and coffee

8:40 – 8:55am

Welcome / Mihi whakatau

• Ah-Leen Rayner, Breast Cancer Foundation NZ

Speaker to be confirmed

8:55 – 10:15am

Opening plenary session
Session chairs: To be confirmed

8:55 – 9:15am

Topic to be confirmed
Rami Rahal, NZ Chief Executive & National Director of Cancer Control, Te Aho o Te Kahu / Cancer Control Agency, New Zealand

9:15 – 9:35am

The Bohemian Rhapsody of new cancer drugs – from “fantasy” to real life
Sara Hurvitz, USA

9:35 – 10:15am

Keep the baby, change the bathwater? How do we run effective, sustainable multidisciplinary team (MDT) meetings in the current era?

9:35 – 9:55am

MDT culture from a European perspective – current practice and future challenges
Peter Dubsky, Switzerland

9:55 – 10:15am

Panel discussion: Sustainable MDT
Peter Barry (UK), Sacha Howell (UK), Icro Meattini (Italy), Sandra O’Toole (Australia), Belinda Yeo (Australia), additional speakers to be confirmed.

10:15 – 10:45am

Morning tea

10:45am – 12:40pm

Early Breast Cancer
Session chairs: To be confirmed

10:50 – 11:10am

Topic to be confirmed
Speaker to be confirmed

11:10 – 11:30am

Bilateral and contralateral risk-reducing mastectomy – changing the conversation
Anna Weiss, USA

11:30 – 11:50am

SOFT and TEXT hit middle age: 15-year outcomes for premenopausal women
Prue Francis, Australia

11:50 – 12:10pm

Topic to be confirmed
Speaker to be confirmed

12:10 – 12:40pm

Debate: It’s safe to omit sentinel lymph node biopsy for all patients with clinically node-negative T1 invasive breast cancer
Yes | Peter Dubsky, Switzerland
No | Peter Barry, UK

12:40 – 1:40pm

Lunch

1:40 – 3:10pm

Parallel session: Advanced breast cancer
Session chair: To be confirmed

1:45 – 2:05pm

The changing shape of first-line treatment for HER2+ ABC
Sara Hurvitz, USA

2:05 – 2:25pm

CAPitello gains – Capivasertib for HR+/HER2- ABC
Sacha Howell, UK

2:25 – 2:45pm

What should we expect for survival of metastatic TNBC these days…and is there a game-changer in sight?
Belinda Yeo, Australia

2:25 – 2:45pm

Short takes from the real world: What we do after progression on first-line treatment for ER+/HER2- ABC
Prue Francis (Australia), Sacha Howell (UK), Sara Hurvitz (USA)

3:00 – 3:10pm

Discussion

1:40 – 3:10pm

Parallel session: Local Heroes - Surgery and Radiation Therapy
Session chair: Peter Chin

1:45 – 2:00pm

Chest wall perforator flaps – reducing the need for mastectomy
Peter Barry, UK

2:00 – 2:15pm

Prepectoral v sub-pectoral implants – surgical and RT considerations
Speaker to be confirmed

2:15 – 2:30pm

The post-NAST axilla – surgery or RT?
Anna Weiss, USA

2:30 – 2:45pm

Interventional techniques for small, screen-detected tumours
Peter Dubsky, Switzerland

2:45 – 3:00pm

Think small – are we ready to adopt cryoablation in routine care?
Speaker to be confirmed

3:00 – 3:10pm

Discussion

3:10 – 3:40pm

Afternoon tea

3:40 – 5:15pm

Breast SIG meeting (open to SIG members, NZ SMOs and NZ nurses)
Session chair: Marion Kuper-Hommel

Draft agenda includes:

• Introduction to clinicial dashboards for Te Rēhita Mate Utaetae – Breast Cancer Foundation National Register

• Clinical trial updates

5:30 – 7:30pm

Welcome reception
The Good Luck Coconut | 39 Jellicoe St, Wynyard Quarter, Auckland

8:00 – 8:30 am

Breakfast and registration open

8:00 – 10:05am

Breakfast of Champions: Championing change in breast cancer care
Session chair: To be confirmed

8:30 – 8:50 am

Endoscopic nipple-sparing mastectomy: new fad or new fact?
Peter Dubsky, Switzerland

8:50 – 9:10 am

Topic to be confirmed
Speaker to be confirmed

9:10 – 9:30am

Biomarker-directed radiation therapy
Icro Meattini, Italy

9:30 – 10:00am

Lowering toxicity: Can we drop adjuvant immunotherapy for TNBC patients achieving pCR with NAST?
Marion Kuper-Hommel, New Zealand

10:00 – 10:05am

Q+A Discussion

10:05 – 10:30am

Morning tea

10:30am – 12:00pm

First things first – new considerations pre-surgery
Session chair: To be confirmed

10:35 – 10:55am

Neoadjuvant endocrine therapy – has its time come?
Belinda Yeo, Australia

10:55 – 11:15am

Neoadjuvant radiotherapy – why, who and how much?
Yvonne Zissiadis, Australia

11:15 – 11:35am

Topic to be confirmed
Speaker to be confirmed

11:35 – 11:50am

What the pathologist looks for after NAST and how we call it
Sandra O’Toole, Australia

11:50 – 12:00pm

Discussion

12:00 – 1:00pm

Lunch

1:00 – 3:05pm

Innovation – how do we do it successfully?
Session chair: To be confirmed

1:05 – 1:35pm

Debate: It’s time to extend NAST to stage 1 TNBC and HER2+ invasive breast cancer
Yes | Sara Hurvitz, USA
No | Belinda Yeo, Australia

1:35 – 1:55pm

Topic to be confirmed
Speaker to be confirmed

1:55 – 2:15pm

Look smarter – implementing innovation in pathology
Sandra O’Toole, Australia

2:15 – 2:35pm

The cutting edge – implementing innovation in surgery
Peter Barry, UK

2:35 – 2:50pm

Radiotherapy for oligometastatic breast cancer
Icro Meattini, Italy

2:50 – 3:05pm

Discussion

3:05 – 3:25pm

Afternoon tea

3:25 – 5:00pm

Prevention / early detection
Session chair: To be confirmed

3:30 – 3:50pm

Chemoprevention – what will it take to make it standard of care?
Anna Weiss, USA

3:50 – 4:05pm

Chemoprevention – what will it take to make it standard of care?
Anna Weiss, USA

4:05 – 4:20pm

Topic to be confirmed
Speaker to be confirmed

4:20 – 5:00pm

Panel discussion: Short takes from the Real World: How has my practice changed after 2025’s meetings?
(NZ chair); Sara Hurvitz (USA), Sacha Howell (UK), Belinda Yeo (Australia), Peter Barry (UK), additional speakers to be confirmed

7:00 – 11:00 pm

Gala Dinner
Auckland Art Gallery | Wellesley Street East, Auckland Central

From 8:00am

Breakfast

8:30am – 12:00pm

Saturday Session: The Future of Follow-Up
Welcome to an interactive session of presentations, discussions and polls
Session chairs: Reuben Broom (NZ) and Prue Francis (Australia)

8:30 – 8:40am

Scene-Setter
Speaker to be confirmed

8:40 – 9:00am

Rethinking follow-up after breast cancer treatment: the 2024 Italian consensus on follow up of early breast cancer in a public health system
Icro Meattini, Italy

9:00 – 9:20am

Table topic group discussion - breakout 1: Pleasure and pain – what’s working in NZ follow-up and what would we like to change?

9:20 – 9:35am

Topic to be confirmed
Speaker to be confirmed

9:35 – 9:55am

Personalized early detection and follow-up in high-risk women (Genetic)
Peter Dubsky, Switzerland

9:55 – 10:10am

Monitoring complex or severe side effects of adjuvant CDK4/6i
Sacha Howell, UK

10:10 – 10:30am

Adherence to endocrine therapy – tackling a growing challenge at scale with intelligent triaging and digital intervention
Breast Cancer Foundation NZ Nurse, New Zealand

10:30 – 10:50am

Morning tea

10:50 – 11:10am

Mamma mia, Here we go again – Treating local recurrence today; follow-up after LRR
Peter Barry, UK

11:10 – 11:30am

The follow-up phase of ABC – balancing survival and survivorship
(Having a normal life; monitoring on toxic treatments)
Sara Hurvitz, USA

11:30 – 11:45am

Table topic group discussion - breakout 2: Do we need new, consistent guidelines for follow-up in New Zealand? How do we start the ball rolling?

11:45 – 11:55am

Feedback

11:55 – 12:00pm

Conference close